| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Rigel Pharmaceuticals Inc (NASDAQ: RIGL)
RIGL Technical Analysis
4
| As on 9th Jun 2023 RIGL SHARE Price closed @ 1.61 and we RECOMMEND Sell for LONG-TERM with Stoploss of 1.86 & Strong Sell for SHORT-TERM with Stoploss of 2.56 we also expect STOCK to react on Following IMPORTANT LEVELS. |
RIGLSHARE Price
| Open | 1.62 | Change | Price | % |
| High | 1.67 | 1 Day | -0.01 | -0.62 |
| Low | 1.58 | 1 Week | 0.29 | 21.97 |
| Close | 1.61 | 1 Month | 0.48 | 42.48 |
| Volume | 1333269 | 1 Year | -0.99 | -38.08 |
| 52 Week High 3.45 | 52 Week Low 0.67 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| RIGL Daily Charts |
RIGL Intraday Charts |
Whats New @ Bazaartrend |
RIGL Free Analysis |
|
|
RIGL Important Levels Intraday
| RESISTANCE | 1.78 |
| RESISTANCE | 1.73 |
| RESISTANCE | 1.69 |
| RESISTANCE | 1.66 |
| SUPPORT | 1.56 |
| SUPPORT | 1.53 |
| SUPPORT | 1.49 |
| SUPPORT | 1.44 |
RIGL Forecast April 2024
| 4th UP Forecast | 2.65 |
| 3rd UP Forecast | 2.32 |
| 2nd UP Forecast | 2.11 |
| 1st UP Forecast | 1.9 |
| 1st DOWN Forecast | 1.32 |
| 2nd DOWN Forecast | 1.11 |
| 3rd DOWN Forecast | 0.9 |
| 4th DOWN Forecast | 0.57 |
RIGL Weekly Forecast
| 4th UP Forecast | 2.15 |
| 3rd UP Forecast | 1.98 |
| 2nd UP Forecast | 1.87 |
| 1st UP Forecast | 1.76 |
| 1st DOWN Forecast | 1.46 |
| 2nd DOWN Forecast | 1.35 |
| 3rd DOWN Forecast | 1.24 |
| 4th DOWN Forecast | 1.07 |
RIGL Forecast2024
| 4th UP Forecast | 7.16 |
| 3rd UP Forecast | 5.38 |
| 2nd UP Forecast | 4.28 |
| 1st UP Forecast | 3.18 |
| 1st DOWN Forecast | 0.04 |
| 2nd DOWN Forecast | -1.06 |
| 3rd DOWN Forecast | -2.16 |
| 4th DOWN Forecast | -3.94 |
Rigel Pharmaceuticals Inc ( NASDAQ USA Symbol : RIGL )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
RIGL Business Profile
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase II clinical trial for the treatment of hospitalized COVID-19 patients; and phase II clinical trial for the treatment of COVID-19. In addition, the company is developing R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California. Address: 1180 Veterans Boulevard, South San Francisco, CA, United States, 94080
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service